Abstract:The emergence of coronavirus disease 2019 (COVID-19) pandemic led to an urgent need to develop therapeutic interventions. Among them, neutralizing antibodies play crucial roles for preventing viral infections and contribute to resolution of infection. Here, we describe the generation of antibody libraries from 17 different COVID-19 recovered patients and screening of neutralizing antibodies to SARS-CoV-2. After 3 rounds of panning, 456 positive phage clones were obtained with high affinity to RBD (receptor binding domain). Then the positive clones were sequenced and reconstituted into whole human IgG for epitope binning assays. After that, all 19 IgG were classified into 6 different epitope groups or Bins. Although all these antibodies were shown to have ability to bind RBD, the antibodies in Bin2 have more superiority to inhibit the interaction between spike protein and angiotensin converting enzyme 2 receptor (ACE2). Most importantly, the antibodies from Bin2 can also strongly bind with mutant RBDs (W463R, R408I, N354D, V367F and N354D/D364Y) derived from SARS-CoV-2 strain with increased infectivity, suggesting the great potential of these antibodies in preventing infection of SARS-CoV-2 and its mutations. Furthermore, these neutralizing antibodies strongly restrict the binding of RBD to hACE2 overexpressed 293T cells. Consistently, these antibodies effectively neutralized pseudovirus entry into hACE2 overexpressed 293T cells. In Vero-E6 cells, these antibodies can even block the entry of live SARS-CoV-2 into cells at only 12.5 nM. These results suggest that these neutralizing human antibodies from the patient-derived antibody libraries have the potential to become therapeutic agents against SARS-CoV-2 and its mutants in this global pandemic.

Neutralizing Antibodies: the Elite Squad to Combat SARS-CoV-2 Infection

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection

Potently neutralizing and protective human antibodies against SARS-CoV-2

Human IgG Neutralizing Monoclonal Antibodies Block SARS-CoV-2 Infection

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Neutralizing monoclonal antibodies against highly pathogenic coronaviruses

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

COVID-19-neutralizing antibodies predict disease severity and survival

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Monoclonal neutralizing antibodies against SARS-COV-2 S protein

Profiling B cell immune responses to identify neutralizing antibodies from convalescent COVID 19 patients

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

Cross-neutralization Antibodies Against SARS-CoV-2 and RBD Mutations from Convalescent Patient Antibody Libraries

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

Cross-neutralization of RBD mutant strains of SARS-CoV-2 by convalescent patient derived antibodies

A SARS-CoV-2 neutralizing antibody with exceptional spike binding coverage and optimized therapeutic potentials

Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies

SARS-CoV-2 neutralizing antibody development strategies